A novel ELISA system demonstrates that fasting serum apoB-48 levels correlate with triglycerides and are markedly elevated in specific hyperlipidemias, serving as a useful parameter for evaluating exogenous lipoprotein metabolism.
Answers are grounded in this paper and cite their sources.
Serum apoB-48 may support evaluation of exogenous lipoprotein metabolism in hyperlipidemia; leaves open its prognostic utility.
The present study was designed to evaluate the metabolism of chylomicron and chylomicron remnants by measuring serum apolipoprotein B-48 (apoB-48) levels in 335 normolipidemic and 253 hyperlipidemic subjects using a novel ELISA system. The distribution of fasting serum apoB-48 levels in normolipidemic subjects varied widely, ranging from <1 to >24 μg/ml (mean, 5.2 ± 3.8 μg/ml; median, 3.9 μg/ml). Serum apoB-48 levels correlated with serum triglyceride (TG) concentrations (r = 0.45, P < 0.001), but not with total cholesterol levels. Serum apoB-48 levels were 7 to 18 times higher in patients with Type I, Type V, and Type III hyperlipidemia, and only slightly higher in patients with Type IIa, Type IIb, and Type IV hyperlipidemia, compared with normolipidemic subjects. The calculated apoB-48/TG ratio was elevated only in patients with dysbetalipoproteinemia (apoE2/2 phenotype). In normolipidemic subjects, oral fat loading resulted in about 2-fold increase in serum apoB-48 levels, with a peak level recorded at 3–4 h postloading, and then returned to the baseline level within 6 h. On the other hand, in patients with dysbetalipoproteinemia, serum apoB-48 levels did not change considerably.Our results indicate that serum apoB-48 is a very useful parameter for evaluating lipoprotein metabolism in exogenous pathways. The present study was designed to evaluate the metabolism of chylomicron and chylomicron remnants by measuring serum apolipoprotein B-48 (apoB-48) levels in 335 normolipidemic and 253 hyperlipidemic subjects using a novel ELISA system. The distribution of fasting serum apoB-48 levels in normolipidemic subjects varied widely, ranging from <1 to >24 μg/ml (mean, 5.2 ± 3.8 μg/ml; median, 3.9 μg/ml). Serum apoB-48 levels correlated with serum triglyceride (TG) concentrations (r = 0.45, P < 0.001), but not with total cholesterol levels. Serum apoB-48 levels were 7 to 18 times higher in patients with Type I, Type V, and Type III hyperlipidemia, and only slightly higher in patients with Type IIa, Type IIb, and Type IV hyperlipidemia, compared with normolipidemic subjects. The calculated apoB-48/TG ratio was elevated only in patients with dysbetalipoproteinemia (apoE2/2 phenotype). In normolipidemic subjects, oral fat loading resulted in about 2-fold increase in serum apoB-48 levels, with a peak level recorded at 3–4 h postloading, and then returned to the baseline level within 6 h. On the other hand, in patients with dysbetalipoproteinemia, serum apoB-48 levels did not change considerably. Our results indicate that serum apoB-48 is a very useful parameter for evaluating lipoprotein metabolism in exogenous pathways. The pathogenic role of hypertriglyceridemia in atherosclerosis has long been elusive. A recent meta analysis of several cohort studies revealed that plasma triglyceride (TG) level is an independent risk factor for cardiovascular diseases (1Hokanson J.E. Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.J. Cardiovasc. Risk. 1996; 3: 213-219Google Scholar). The relationship between plasma TG levels and atherosclerotic diseases has often been discussed in relation to postprandial hyperlipidemia (2Patsch J.R. Miesenbock G. Hopferwieser T. Muhlberger V. Knapp E. Dunn J.D. Gotto Jr., A.M. Patsch W. Relation of triglyceride metabolism and coronary artery disease.Arterioscler. Thromb. 1992; 12: 1336-1345Google Scholar, 3Zilversmit D.B. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins.Clin. Chem. 1995; 41: 153-158Google Scholar, 4Miensenbock G. Patsch J.R. Postprandial hyperlipidemia: the search for the atherogenic lipoprotein.Curr. Opin. Lipidol. 1992; 3: 196-201Google Scholar, 5Patsch J.R. Triglyceride-rich lipoproteins and atherosclerosis.Atherosclerosis. 1994; 110: 23-26Google Scholar, 6Havel R.J. Postprandial hyperlipidemia and remnant lipoproteins.Curr. Opin. Lipidol. 1994; 5: 102-119Google Scholar, 7Karpe F. Hamsten A. Postprandial lipoprotein metabolism and atherosclerosis.Curr. Opin. Lipidol. 1995; 6: 123-129Google Scholar). Several studies have pointed to the relationship between the impaired metabolism of postprandial TG-rich lipoproteins (TRLs) and the presence or development of coronary heart disease (CHD). A mechanistic hypothesis linking the postprandial generation of TRL remnants (products of lipolytic degradation of TRL produced by the liver, VLDL, and by the intestine chylomicrons) to the development of atherosclerosis was formulated almost 20 years ago by Zilversmit (8Zilversmit D.B. Atherogenesis: a postprandial phenomenon.Circulation. 1979; 60: 473-485Google Scholar). TG-depleted remnants are considered to be atherogenic because they can penetrate the mucosal lining of the arterial wall and become entrapped within the subendothelial space. Thus, accurate evaluation of the kinetics of chylomicron and chylomicron remnants is very important. Chylomicrons are secreted by the intestine after fat ingestion. Chylomicron particles contain apolipoprotein B-48 (apoB-48) as the structural protein, which in humans is formed exclusively in the intestine after tissue-specific editing of the apoB-100 mRNA (9Chan L. Chang B.H. Nakamuta M. Li W.H. Smith L.C. Apobec-1 and apolipoprotein B mRNA editing.Biochim. Biophys. Acta. 1997; 1345: 11-26Google Scholar, 10Davidson N.O. Shelness G.S. Apolipoprotein B: mRNA editing, lipoprotein assembly, and presecretory degradation.Annu. Rev. Nutr. 2000; 20: 169-193Google Scholar). Different methods are used for estimation of postprandial lipoproteins. A number of studies have made use of retinyl palmitate (RP) labeling of chylomicrons, together with postprandial plasma TG quantification. The RP technique has shortcomings as it has recently been shown that RP can exchange between lipoprotein species in plasma, implying that plasma RP is not always synonymous with the presence of chylomicron remnants (11Lemieux S. Fontani R. Uffelman K.D. Lewis G.F. Steiner G. Apolipoprotein B-48 and retinyl palmitate are not equivalent markers of postprandial intestinal lipoproteins.J. Lipid Res. 1998; 39: 1964-1971Google Scholar). Furthermore, the RP does not provide uniform labeling of the chylomicrons, as it is probable that the larger species carry more RP than do the smaller ones. In contrast, the use of apoB-48 and apoB-100 quantification in TRL provides a good estimate of lipoprotein particle numbers. Therefore, a more direct assay of apoB-48 level has been through the monitoring of the kinetics of chylomicrons and their remnants in vivo; however, their quantification has been limited because of their low concentrations in plasma and lack of specific antibodies. A wide range of fasting apoB-48 values has been reported by different groups (11Lemieux S. Fontani R. Uffelman K.D. Lewis G.F. Steiner G. Apolipoprotein B-48 and retinyl palmitate are not equivalent markers of postprandial intestinal lipoproteins.J. Lipid Res. 1998; 39: 1964-1971Google Scholar, 12Schneeman B.O. Kotite L. Todd K.M. Havel R.J. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans.Proc. Natl. Acad. Sci. USA. 1993; 90: 2069-2073Google Scholar, 13Karpe F. Hamsten A. Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE.J. Lipid Res. 1994; 35: 1311-1317Google Scholar, 14Lovegrove J.A. Isherwood S.G. Jackson K.G. Williams C.M. Gould B.J. Quantitation of apolipoprotein B-48 in triacylglycerol-rich lipoproteins by a specific enzyme-linked immunosorbent assay.Biochim. Biophys. Acta. 1996; 1301: 221-229Google Scholar, 15Smith D. Proctor S.D. Mamo J.C.L.A. Highly sensitive assay for quantitation of apolipoprotein B-48 using an antibody to human apolipoprotein B and enhanced chemiluminescence.Ann. Clin. Biochem. 1997; 34: 185-189Google Scholar, 16Smith D. Watts G.F. Dane-Stewart C. Mamo J.C.L. Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state.Eur. J. Clin. Invest. 1999; 29: 204-209Google Scholar, 17Lorec A.M. Juhel C. Pafumi Y. Portugal H. Pauli A.M. Lairon D. Defoort C. Determination of apolipoprotein B-48 in plasma by a competitive ELISA.Clin. Chem. 2000; 46: 1638-1642Google Scholar), likely because no standard method has yet been established. Furthermore, the results are expressed as either TRL apoB-48 or plasma apoB-48. These studies used the following assays for estimation of apoB-48 levels: SDS-PAGE (11Lemieux S. Fontani R. Uffelman K.D. Lewis G.F. Steiner G. Apolipoprotein B-48 and retinyl palmitate are not equivalent markers of postprandial intestinal lipoproteins.J. Lipid Res. 1998; 39: 1964-1971Google Scholar, 12Schneeman B.O. Kotite L. Todd K.M. Havel R.J. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans.Proc. Natl. Acad. Sci. USA. 1993; 90: 2069-2073Google Scholar, 13Karpe F. Hamsten A. Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE.J. Lipid Res. 1994; 35: 1311-1317Google Scholar), SDS-PAGE coupled with Western blotting (15Smith D. Proctor S.D. Mamo J.C.L.A. Highly sensitive assay for quantitation of apolipoprotein B-48 using an antibody to human apolipoprotein B and enhanced chemiluminescence.Ann. Clin. Biochem. 1997; 34: 185-189Google Scholar, 16Smith D. Watts G.F. Dane-Stewart C. Mamo J.C.L. Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state.Eur. J. Clin. Invest. 1999; 29: 204-209Google Scholar), and a competitive ELISA with polyclonal antibodies (14Lovegrove J.A. Isherwood S.G. Jackson K.G. Williams C.M. Gould B.J. Quantitation of apolipoprotein B-48 in triacylglycerol-rich lipoproteins by a specific enzyme-linked immunosorbent assay.Biochim. Biophys. Acta. 1996; 1301: 221-229Google Scholar, 17Lorec A.M. Juhel C. Pafumi Y. Portugal H. Pauli A.M. Lairon D. Defoort C. Determination of apolipoprotein B-48 in plasma by a competitive ELISA.Clin. Chem. 2000; 46: 1638-1642Google Scholar). The Western blotting method, however, is very time-consuming and is less quantitative than the ELISA method, and the continuous supply of polyclonal antibodies of equal reactivity for long-term surveys remains questionable. In this regard, we recently developed monoclonal antibodies against apoB-48 and reported their specificity and possible usage for ELISA assay system (18Uchida Y. Kurano Y. Ito S. Establishment of monoclonal antibody against human ApoB-48 and measurement of ApoB-48 in serum by ELISA method.J. Clin. Lab. Anal. 1998; 12: 289-292Google Scholar). In the present study, we report a novel ELISA system for measurement of serum apoB-48. We also used the novel assay to measure fasting and postprandial serum apoB-48 levels in 335 normolipidemic and 253 subjects with various forms of hyperlipidemia. We confirm that the fasting apoB-48 concentration determined by our ELISA system closely represents lipoprotein metabolism in exogenous pathways. The subjects investigated were a consecutive series of 574 healthy volunteers who were employees of a single company and visited the hospital for annual general health checkup. Of the total sample, 335 subjects were considered normolipidemic [total cholesterol (TC) < 220 mg/dl and TG < 150 mg/dl], while the remaining 239 healthy subjects were considered hyperlipidemic (TC ⩾ 220 mg/dl and/or TG ⩾ 150 mg/dl). The phenotype of hyperlipidemic subjects was also determined based on the criteria proposed by the Research Committee for Primary Hyperlipidemia of the Ministry of Health and Welfare of Japan: 1) Type IIa hyperlipidemia: in the presence of hypercholesterolemia (TC ⩾ 220 mg/dl and TG < 150 mg/dl); 2) Type IIb hyperlipidemia: in the presence of both hypercholesterolemia and hypertriglyceridemia (TC ⩾ 220 mg/dl and TG ⩾ 150 mg/dl), but serum TG level was < 500 mg/dl; 3) Type IV hyperlipidemia: in the presence of hypertriglyceridemia (TC < 220 mg/dl and TG ⩾ 150 mg/dl), but serum TG level was <500 mg/dl; and 4) Type V hyperlipidemia: in the presence of both hypercholesterolemia and hypertriglyceridemia (TC ⩾ 220 mg/dl and TG ⩾ 150 mg/dl), but serum TG level was > 500 mg/dl. Two patients with lipoprotein lipase (LPL) deficiency (Type I hyperlipidemia), five patients with familial dysbetalipoproteinemia (Type III hyperlipidemia), and seven Type V hyperlipidemic patients who were referred to Osaka University Hospital for the examination of hyperlipidemia were also added to the hyperlipidemic group, because the original hyperlipidemic group contained no Type I, no Type III, and only one subject with Type V hyperlipidemia. LPL deficiency was determined by measuring LPL activity in postheparin plasma 15 min after injection of sodium heparin (50 IU/kg dysbetalipoproteinemia was based on the presence of hypercholesterolemia and an and the presence of a on of serum lipoproteins. The and of 253 hyperlipidemic and 335 normolipidemic subjects are shown in of 335 normolipidemic subjects and of five familial subjects to in study for evaluation by oral fat subjects their to in this of hyperlipidemic and normolipidemic subjects ± ± < ± < ± < < ± < ± ± < ± < ± < ± ± < ± ± < ± < ± < ± < ± < ± = = ± ± < ± < ± < ± < ± ± < ± < ± < ± ± < ± < = ± ± < ± < ± < ± < ± = ± ± < ± < ± ± < ± ± < ± ± < ± < ± < ± ± ± ± ± ± ± ± ± ± ± ± ± total ± P < P < P < P < P < P < P < P < P < P < P < P < in a total ± was in a after at a h Serum was by at and at used for of apoB-48. The of the serum was at for that were within Serum and TG levels were determined by Serum cholesterol level was determined by the method M. of a method for serum Chem. 2000; Scholar). The presence of a of serum lipoproteins was determined by phenotype was determined by Serum apoB-48 levels were by a ELISA using apoB-48 monoclonal antibodies as reported with (18Uchida Y. Kurano Y. Ito S. Establishment of monoclonal antibody against human ApoB-48 and measurement of ApoB-48 in serum by ELISA method.J. Clin. Lab. Anal. 1998; 12: 289-292Google Scholar). A was with monoclonal antibodies by at by with and with containing Serum were with and of the serum was used for the The monoclonal antibodies were used as the The of with human apoB-48 by S.G. B.J. of forms of human apolipoprotein B in that the of apolipoprotein B has a on the of the secreted lipoproteins.J. Chem. Scholar, Y. of human lipoproteins in with apoB-48 of apoB-48 of Thromb. 1995; were and used as a standard because they be in and In the standard was with of serum and a standard was The range and of the standard were to and The serum were as to be in the The specificity of the assay was (18Uchida Y. Kurano Y. Ito S. Establishment of monoclonal antibody against human ApoB-48 and measurement of ApoB-48 in serum by ELISA method.J. Clin. Lab. Anal. 1998; 12: 289-292Google Scholar). The of for with and low concentrations were and = The were and = The apoB-48 concentration of the standard was determined using human apoB-48 as the The apoB-48 was from human plasma by the < was by to the method of Havel R.J. The distribution and of lipoproteins in human Clin. Invest. Scholar). The < was through the times to The apoB-48 was from the using the The of the apoB-48 was to be on SDS-PAGE with The apoB-48 concentration of the standard was determined with assay and by the of the on the SDS-PAGE with a concentration of human apoB-100 of the range from to that the of apoB-48 and apoB-100 were considered the as reported F. Hamsten A. Uffelman Steiner G. Apolipoprotein 1996; Scholar). The the of the of the < as was also used to the concentration of the and the results as the apoB-48. containing fat was after a h study subject within The study subjects were to only a of the study to against was and and 6 h after the fat by serum were expressed as ± were using The a was used to the between were determined to the relationship between different was at P < the distribution of fasting serum apoB-48 levels in 335 normolipidemic subjects. The apoB-48 levels were a wide range from <1 μg/ml to >24 μg/ml mg/dl). The level in this group was 5.2 ± 3.8 the was 3.9 and the range for subjects was the between serum apoB-48 levels and and TG serum apoB-48 levels were against serum TG concentrations in 335 normolipidemic subjects. Serum apoB-48 levels correlated with serum TG levels (r = 0.45, P < 0.001), but was no between serum apoB-48 and levels. In to the of measuring serum apoB-48 levels in the evaluation of lipoprotein the fasting serum apoB-48 levels in patients with various of hyperlipidemia were determined to the apoB-48 levels were seven to 18 times higher in the subjects with Type I and and the patients with Type V ± hyperlipidemia, with with familial dysbetalipoproteinemia also levels of serum apoB-48 ± = that chylomicron remnants in The apoB-48 levels in Type IIa ± 3.8 = Type IIb ± = and Type IV ± = hyperlipidemic subjects were higher than the but increase was in with the The ratio of serum apoB-48 levels to serum TG concentrations was calculated in subjects with various forms of hyperlipidemia and in normolipidemic subjects, and is shown in the apoB-48/TG ratio was within the range in Type I and Type V hyperlipidemic subjects, it was in patients with dysbetalipoproteinemia ± P < The apoB-48/TG ratio was more than in five subjects. In to the fasting apoB-48 levels lipoprotein metabolism in exogenous the oral fat loading was in normolipidemic and familial subjects. the serum TG level apoB-48 level and apoB-48/TG ratio in normolipidemic or subjects at the In normolipidemic subjects, serum apoB-48 levels to about with the peak at 3–4 h after oral fat then returned to the baseline level within 6 h. In the group, the fasting levels of apoB-48 were ± and the postprandial peak levels were ± The serum apoB-48 levels to postprandial TG to a apoB-48/TG The fasting and postprandial serum TG levels in subjects with familial dysbetalipoproteinemia were higher at with a to of normolipidemic subjects. The postprandial apoB-48 levels in subjects at levels and to be and the apoB-48/TG after oral fat Several have reported a wide range of fasting apoB-48 levels from μg/ml to μg/ml (11Lemieux S. Fontani R. Uffelman K.D. Lewis G.F. Steiner G. Apolipoprotein B-48 and retinyl palmitate are not equivalent markers of postprandial intestinal lipoproteins.J. Lipid Res. 1998; 39: 1964-1971Google Scholar, 12Schneeman B.O. Kotite L. Todd K.M. Havel R.J. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans.Proc. Natl. Acad. Sci. USA. 1993; 90: 2069-2073Google Scholar, 13Karpe F. Hamsten A. Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE.J. Lipid Res. 1994; 35: 1311-1317Google Scholar, 14Lovegrove J.A. Isherwood S.G. Jackson K.G. Williams C.M. Gould B.J. Quantitation of apolipoprotein B-48 in triacylglycerol-rich lipoproteins by a specific enzyme-linked immunosorbent assay.Biochim. Biophys. Acta. 1996; 1301: 221-229Google Scholar, 15Smith D. Proctor S.D. Mamo J.C.L.A. Highly sensitive assay for quantitation of apolipoprotein B-48 using an antibody to human apolipoprotein B and enhanced chemiluminescence.Ann. Clin. Biochem. 1997; 34: 185-189Google Scholar, 16Smith D. Watts G.F. Dane-Stewart C. Mamo J.C.L. Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state.Eur. J. Clin. Invest. 1999; 29: 204-209Google Scholar, 17Lorec A.M. Juhel C. Pafumi Y. Portugal H. Pauli A.M. Lairon D. Defoort C. Determination of apolipoprotein B-48 in plasma by a competitive ELISA.Clin. Chem. 2000; 46: 1638-1642Google Scholar), within which our ± 3.8 also The wide range from the lack of a method of measurement and the of the results as either TRL apoB-48 or plasma apoB-48. the the ELISA system with monoclonal antibodies is to values the time-consuming of In the normolipidemic subjects with fasting serum apoB-48 levels, we not of apoB-48 on the subjects because the were and of and to a h may the fasting levels of studies are to the of levels of fasting serum apoB-48 in subjects. We that the fasting serum apoB-48 concentrations the impaired of chylomicron and/or chylomicron remnants from the hyperlipidemia), and this is by the of Smith D. Watts G.F. Dane-Stewart C. Mamo J.C.L. Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state.Eur. J. Clin. Invest. 1999; 29: 204-209Google Scholar), a relationship between fasting plasma concentrations of apoB-48 and postprandial kinetics of retinyl and the relation of postprandial hyperlipidemia and the presence or development of is it be also to fasting serum apoB-48 level is also to the of The serum apoB-48 levels in patients with dysbetalipoproteinemia who do not have levels of chylomicrons of atherogenic chylomicron The apoB-48/TG ratio the of dysbetalipoproteinemia from Type I and Type V hyperlipidemia. one chylomicron particle only one of serum apoB-48 concentrations the number of chylomicrons and chylomicron remnant The serum apoB-48 levels and apoB-48/TG ratio in patients with dysbetalipoproteinemia indicate an number of smaller while the apoB-48 levels and low apoB-48/TG ratio in Type I and Type V hyperlipidemia both an number of the particles and of the particles with These results are with elevated levels of chylomicrons in Type I and Type V hyperlipidemia and of chylomicron remnants in is to dysbetalipoproteinemia from Type IIb or Type V hyperlipidemia based on serum levels familial dysbetalipoproteinemia is a very atherogenic patients with this be more with to and other to against or to the development of atherosclerotic this accurate of this of hyperlipidemia is A of methods for the of dysbetalipoproteinemia have been proposed to the time-consuming and of These a total TG ratio of and particle total TG ratio of both of which the of TRL in a of and the is reported to be more sensitive T. J. Havel R.J. of to serum total is an to and methods in the of familial III Chem. 1999; Scholar). cholesterol is to a of cholesterol in lipoproteins and of a of with and Thus, serum apoB-48 levels and the apoB-48/TG ratio in with serum concentrations also provide an accurate and of with Type IIa, Type IIb, and Type IV hyperlipidemia only a increase in serum apoB-48 levels, elevated TG however, it is that several subjects with Type IV hyperlipidemia almost the levels of apoB-48 as with Type V hyperlipidemia not The results indicate of metabolism in the exogenous and of chylomicrons and/or chylomicron remnants in subjects. In this Type IV hyperlipidemic subjects with elevated apoB-48 levels be as Type V hyperlipidemic they have serum levels. Thus, this the of the of based on serum and TG levels, with to patients with The of apoB-48 response after oral fat loading that of TG response in normolipidemic subjects, that serum apoB-48 concentrations closely exogenous lipoprotein metabolism in the postprandial The peak serum apoB-48 levels and the level of 3–4 h after fat loading are almost in with reported by other (11Lemieux S. Fontani R. Uffelman K.D. Lewis G.F. Steiner G. Apolipoprotein B-48 and retinyl palmitate are not equivalent markers of postprandial intestinal lipoproteins.J. Lipid Res. 1998; 39: 1964-1971Google Scholar, 12Schneeman B.O. Kotite L. Todd K.M. Havel R.J. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans.Proc. Natl. Acad. Sci. USA. 1993; 90: 2069-2073Google Scholar, 13Karpe F. Hamsten A. Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE.J. Lipid Res. 1994; 35: 1311-1317Google Scholar, 14Lovegrove J.A. Isherwood S.G. Jackson K.G. Williams C.M. Gould B.J. Quantitation of apolipoprotein B-48 in triacylglycerol-rich lipoproteins by a specific enzyme-linked immunosorbent assay.Biochim. Biophys. Acta. 1996; 1301: 221-229Google Scholar, 15Smith D. Proctor S.D. Mamo J.C.L.A. Highly sensitive assay for quantitation of apolipoprotein B-48 using an antibody to human apolipoprotein B and enhanced chemiluminescence.Ann. Clin. Biochem. 1997; 34: 185-189Google Scholar, 16Smith D. Watts G.F. Dane-Stewart C. Mamo J.C.L. Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state.Eur. J. Clin. Invest. 1999; 29: 204-209Google Scholar, 17Lorec A.M. Juhel C. Pafumi Y. Portugal H. Pauli A.M. Lairon D. Defoort C. Determination of apolipoprotein B-48 in plasma by a competitive ELISA.Clin. Chem. 2000; 46: 1638-1642Google Scholar, S.D. of apoB-48 and apoB-100 triglyceride-rich lipoproteins to postprandial in the plasma concentration of TRL and retinyl Lipid Res. 1993; 34: Scholar). On the other hand, serum apoB-48 levels in subjects did not serum TG concentrations that a increase and in the postprandial The change of TG and apoB-48 levels in dysbetalipoproteinemia was by a continuous in the apoB-48/TG ratio after the fat with the response of apoB-48 in normolipidemic subjects, the levels of serum apoB-48 after fat loading in dysbetalipoproteinemia is of The lack of increase in apoB-48 levels after fat loading may only the of a increase by the very fasting levels. the continuous of the apoB-48/TG ratio the that the TG levels after fat loading in dysbetalipoproteinemia are more to of lipoprotein particles with TG than to particle numbers. The of the between subjects with and dysbetalipoproteinemia in response of apoB-48 and TG after fat loading In in the present study we a novel ELISA system for measurement of serum apoB-48 and the of measurement for the evaluation of lipoprotein metabolism in exogenous pathways. Serum apoB-48 level may become a for the of postprandial hyperlipidemia, one of the risk for coronary studies are to the relationship between serum apoB-48 levels and atherosclerotic cardiovascular The to and for their was by a for Research and to from the Ministry of and in coronary heart disease of lipoprotein lipase particle retinyl palmitate total cholesterol triglyceride TG-rich lipoprotein
No takes yet. Share an insight, caveat, or question.
Sakai et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: